QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.075648v1 312/2/742    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pepinsky, R. B. Articles by Scott, D. M. Search for Related Content PubMed PubMed Citation Articles by Pepinsky, R. B. Articles by Scott, D. M.

INFLAMMATION AND IMMUNOPHARMACOLOGY

Design, Synthesis, and Analysis of a Polyethelene Glycol-Modified (PEGylated) Small Molecule Inhibitor of Integrin 41 with Improved Pharmaceutical Properties

Biogen Idec, Inc., Cambridge Center, Cambridge, MA

Integrin 41 plays an important role in inflammatory processes by regulating the migration of leukocytes into inflamed tissues. Previously, we identified BIO5192 [2(S)-{[1-(3,5-dichloro-benzenesulfonyl)-pyrrolidine-2(S)-carbonyl]-amino}-4-[4-methyl-2(S)-(methyl-{2-[4-(3-o-tolyl-ureido)-phenyl]-acetyl}-amino)-pentanoylamino]-butyric acid], a highly selective and potent (K_D of 9 pM) small molecule inhibitor of 41. Although BIO5192 is efficacious in various animal models of inflammatory disease, high doses and daily treatment of the compound are needed to achieve a therapeutic effect because of its relatively short serum half-life. To address this issue, polyethylene glycol modification (PEGylation) was used as an approach to improve systemic exposure. BIO5192 was PEGylated by a targeted approach in which derivatizable amino groups were incorporated into the molecule. Two sites were identified that could be modified, and from these, five PEGylated compounds were synthesized and characterized. One compound, 2a-PEG (K_D of 19 pM), was selected for in vivo studies. The pharmacokinetic and pharmacodynamic properties of 2a-PEG were dramatically improved relative to the unmodified compound. The PEGylated compound was efficacious in a rat model of experimental autoimmune encephalomyelitis at a 30-fold lower molar dose than the parent compound and required only a once-a-week dosing regimen compared with a daily treatment for BIO5192. Compound 2a-PEG was highly selective for 41. These studies demonstrate the feasibility of PEGylation of 41-targeted small molecules with retention of activity in vitro and in vivo. 2a-PEG, and related compounds, will be valuable reagents for assessing 41 biology and may provide a new therapeutic approach to treatment of human inflammatory diseases.

Address correspondence to: R. Blake Pepinsky, Biogen Idec, Inc., 14 Cambridge Center, Cambridge, MA 02142. E-mail: blake.pepinsky{at}biogenidec.com

This article has been cited by other articles:

				T. Ecoiffier, J. El Annan, S. Rashid, D. Schaumberg, and R. Dana Modulation of Integrin {alpha}4{beta}1 (VLA-4) in Dry Eye Disease Arch Ophthalmol, December 1, 2008; 126(12): 1695 - 1699. [Abstract] [Full Text] [PDF]